Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

• Status: Withdrawn
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Ribavirin

Criteria

Inclusion Criteria:

• Males and females, ≥ 18 years of age

• Subjects chronically infected with Hepatitis C virus (HCV) genotype 1,2,3 or 4

• HCV RNA viral load ≥ 10,000 IU/mL

• Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population)

• Body Mass Index (BMI) of 18 to 35 kg/m2

• Seronegative for Hepatitis C virus (HIV) and Hepatitis B

Exclusion Criteria:

• Evidence of decompensated liver disease

• Evidence of medical condition contributing to chronic liver disease other than HCV